9926.HK

Akeso, Inc. [9926.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

9926.HK Stock Summary

Earnings have grown 271.26% per last year.

EPS has been increasing for the past 3 quarters (Quarter statements)

EPS has increased from the previous quarter and is now positive. (Quarter statements)

Became profitable this year

Earnings are expected to fall -100% next year

9926.HK has less than 1 year of cash runway

Top 10 Correlated Stocks

9926.HK

In the News

9926.HK Financial details

Company Rating

Strong Buy

Market Cap

42.77B

Income

706.62M

Revenue

4.61B

Book val./share

6.66

Cash/share

6.94

Dividend

Dividend %

Employees

2.78K

Optionable

Shortable

Yes

Earnings

18 Mar 2024

P/E

-31.27

Forward P/E

PEG

1.95

P/S

44.17

P/B

13.8

P/C

6.33

P/FCF

-18.11

Quick Ratio

1.68

Current Ratio

2.25

Debt / Equity

0.49

LT Debt / Equity

0.44

EPS (TTM)

0.8

EPS next Y

EPS next Q

EPS this Y

7.58%

EPS next Y

EPS next 5Y

EPS last 5Y

51.15%

Revenue last 5Y

212.16%

Revenue Q/Q

445.11%

EPS Q/Q

-570.31%

SMA20

-6%

SMA50

14.63%

SMA100

Inst Own

Inst Trans

ROA

-21%

ROE

-40%

ROC

-0.33%

Gross Margin

89%

Oper. Margin

-165%

Profit Margin

-139%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

30.3-55.0

52W High

-20.18%

52W Low

+46.33%

RSI

Rel Volume

1.45

Avg Volume

4.78M

Volume

6.93M

Perf Week

-9.76%

Perf Month

-1.9%

Perf Quarter

12.56%

Perf Half Y

13.14%

Beta

0.484

Volatility

1.79%, 2.15%

Prev Close

-3.3%

Price

43.9

Change

-6.3%

9926.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0	0.69	0	0.28	1.02
Net income per share	-0.18	-2.74	-1.65	-1.32	-1.42
Operating cash flow per share	-0.16	-2.13	-0.98	-1.23	-1.5
Free cash flow per share	-0.26	-3.46	-1.69	-2.1	-2.44
Cash per share	0.54	11.53	4.27	3.24	2.54
Book value per share	0.58	-0.06	5.06	3.88	3.19
Tangible book value per share	0.58	2.09	5.48	4.02	3.08
Share holders equity per share	0.58	-0.06	5.06	3.88	3.19
Interest debt per share	0.09	12.81	0.31	1.06	2.32
Market cap	16.27B	2.23B	20.16B	22.64B	31.33B
Enterprise value	16.02B	1.2B	17.68B	20.86B	31.11B
P/E ratio	-116.19	-7.93	-19.46	-21.06	-26.81
Price to sales ratio	5.76K	31.52	0	100.35	37.4
POCF ratio	-131.85	-10.17	-32.64	-22.61	-25.26
PFCF ratio	-82.36	-6.28	-18.99	-13.21	-15.54
P/B Ratio	36.88	-351.68	6.33	7.16	11.89
PTB ratio	36.88	-351.68	6.33	7.16	11.89
EV to sales	5.67K	16.93	0	92.45	37.14
Enterprise value over EBITDA	-113.65	-4.29	-17.54	-15.85	-21.52
EV to operating cash flow	-129.83	-5.47	-28.62	-20.83	-25.08
EV to free cash flow	-81.1	-3.37	-16.65	-12.17	-15.43
Earnings yield	-0.01	-0.13	-0.05	-0.05	-0.04
Free cash flow yield	-0.01	-0.16	-0.05	-0.08	-0.06
Debt to equity	0.15	-206.8	0.06	0.27	0.71
Debt to assets	0.1	0.79	0.05	0.18	0.34
Net debt to EBITDA	1.76	3.7	2.47	1.35	0.15
Current ratio	5.31	10.49	17.66	4.81	2.25
Interest coverage	-58.19	-51.07	0	-131.77	-35.52
Income quality	0.8	0.65	0.52	0.93	1.06
Dividend Yield	0	0	0	0.04	0
Payout ratio	0	0	0	-0.78	0
Sales general and administrative to revenue	2.39	0.78	0	1.08	0.24
Research and developement to revenue	57	4.35	0	4.98	1.58
Intangibles to total assets	0.07	0	0	0	0
Capex to operating cash flow	0.6	0.62	0.72	0.71	0.63
Capex to revenue	-26.24	-1.92	0	-3.16	-0.93
Capex to depreciation	-5.72	-8.32	-20.51	-12.49	-7.49
Stock based compensation to revenue	0	0	0	0.19	0.05
Graham number	1.55	1.95	13.7	10.72	10.09
ROIC	-0.27	-0.18	-0.24	-0.29	-0.28
Return on tangible assets	-0.23	-0.17	-0.27	-0.22	-0.21
Graham Net	0.24	-2.55	3.54	1.59	-0.58
Working capital	371.28M	1.14B	2.83B	2.5B	1.7B
Tangible asset value	440.79M	215.21M	3.45B	3.28B	2.54B
Net current asset value	293.89M	-201.27M	2.6B	1.63B	110.54M
Invested capital	0.15	-206.8	0.06	0.27	0.71
Average receivables	0	-50.44M	-55.39M	-4.08M	186.45M
Average payables	0	45.14M	77.77M	159.46M	257.63M
Average inventory	0	16.25M	38.38M	128.93M	269.23M
Days sales outstanding	-12.93K	-3.98	0	164.76	118.11
Days payables outstanding	0	0	21.6K	2.49K	1.09K
Days of inventory on hand	0	0	11.75K	2.38K	1.21K
Receivables turnover	-0.03	-91.81	0	2.22	3.09
Payables turnover	0	0	0.02	0.15	0.33
Inventory turnover	0	0	0.03	0.15	0.3
ROE	-0.32	44.35	-0.33	-0.34	-0.44
Capex per share	-0.1	-1.32	-0.71	-0.87	-0.94

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2021-06-30	2021-12-31	2022-06-30	2022-12-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.16	0.12	0.2	0.81	4.39
Net income per share	-0.52	-0.8	-0.77	-0.64	3.01
Operating cash flow per share	-0.43	-0.8	-0.71	-0.79	3.43
Free cash flow per share	-0.79	-1.31	-1.08	-1.36	3.01
Cash per share	4.94	3.96	3.21	3.07	6.94
Book value per share	5.7	4.74	3.76	3.54	6.66
Tangible book value per share	6.12	5	3.94	3.63	6.71
Share holders equity per share	5.7	4.74	3.76	3.54	6.66
Interest debt per share	0.66	1.28	1.91	2.52	3.26
Market cap	42.51B	22.66B	16.02B	31.74B	27.36B
Enterprise value	39.25B	20.48B	14.97B	31.5B	25.48B
P/E ratio	-25.01	-8.72	-6.35	-14.75	2.71
Price to sales ratio	330.54	233.55	98.17	47.06	7.44
POCF ratio	-122.69	-34.61	-27.58	-48.11	9.53
PFCF ratio	-65.94	-21.2	-18.25	-27.88	10.85
P/B Ratio	9.15	5.85	5.24	10.73	4.9
PTB ratio	9.15	5.85	5.24	10.73	4.9
EV to sales	305.21	211.08	91.73	46.7	6.93
Enterprise value over EBITDA	-79.76	-24.85	-21.17	-42.63	10.7
EV to operating cash flow	-113.29	-31.28	-25.77	-47.75	8.88
EV to free cash flow	-60.89	-19.16	-17.05	-27.67	10.1
Earnings yield	-0.01	-0.03	-0.04	-0.02	0.09
Free cash flow yield	-0.02	-0.05	-0.05	-0.04	0.09
Debt to equity	0.12	0.27	0.51	0.71	0.49
Debt to assets	0.09	0.18	0.27	0.34	0.28
Net debt to EBITDA	6.62	2.64	1.49	0.32	-0.79
Current ratio	17.22	4.81	2.67	2.25	6.43
Interest coverage	0	0	0	0	0
Income quality	0.82	1.01	0.92	1.23	1.14
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	0.56	1.76	0.57	0.16	0.03
Research and developement to revenue	4.38	5.77	3.65	1.08	0.16
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.86	0.63	0.51	0.73	-0.12
Capex to revenue	-2.32	-4.27	-1.82	-0.71	-0.09
Capex to depreciation	-16.28	-10.7	-6.54	-8.23	-5.25
Stock based compensation to revenue	1.17	-1.1	0.16	0.02	0
Graham number	8.18	9.21	8.09	7.16	21.26
ROIC	-0.09	-0.14	-0.15	-0.11	0.28
Return on tangible assets	-0.07	-0.11	-0.11	-0.09	0.26
Graham Net	4.21	2.23	0.6	-0.05	2.52
Working capital	4.11B	3.05B	2.18B	1.91B	5.47B
Tangible asset value	4.98B	4.09B	3.2B	3.03B	5.62B
Net current asset value	3.58B	2.07B	860.54M	303.26M	2.38B
Invested capital	0.12	0.27	0.51	0.71	0.49
Average receivables	0	0	0	0	0
Average payables	0	0	0	0	0
Average inventory	0	0	0	0	0
Days sales outstanding	114.46	319.07	241.56	58.8	7.63
Days payables outstanding	8.35K	718.96	1.03K	418.29	333.86
Days of inventory on hand	9.2K	685.17	1.12K	462.82	355.35
Receivables turnover	0.79	0.28	0.37	1.53	11.8
Payables turnover	0.01	0.13	0.09	0.22	0.27
Inventory turnover	0.01	0.13	0.08	0.19	0.25
ROE	-0.09	-0.17	-0.21	-0.18	0.45
Capex per share	-0.37	-0.51	-0.36	-0.57	-0.42

9926.HK Frequently Asked Questions

What is Akeso, Inc. stock symbol ?

Akeso, Inc. is a CN stock and trading under the symbol 9926.HK

What is Akeso, Inc. stock quote today ?

Akeso, Inc. stock price is $43.9 today.

Is Akeso, Inc. stock public?

Yes, Akeso, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 4.78M
Market Capitalization 42.77B
Employee 2.78K
CEO Dr. Yu Xia Ph.D.
Headquarters Zhongshan,CN
IPO Date 2020-04-24
Website https://www.akesobio.com

Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL), HCC, head and neck cancer, thyroid cancer, mesothelioma and thymic cancer, ESCC, UC, GC, GEJ, cholangiocarcinoma, neuroendocrine tumor, and mismatch repair deficient solid tumor; AK117, a CD47 monoclonal antibody to treat myelodysplastic syndrome, acute myeloid leukemia, GC, GEJ, ESCC, TNBC, HNSCC, R/R cHL, NPC, NSCLC, and solid tumors/lymphoma; AK119, a CD73 monoclonal antibody for treating solid tumors; and AK109, a VEGFR-2 monoclonal antibody to treat solid tumors and gastric cancer. In addition, the company develops AK120, an IL-4R monoclonal antibody to treat moderate-to-severe atopic dermatitis and asthma, and eosinophilic esophagitis; AK101, an IL-12/IL-23 monoclonal antibody to treat moderate-to-severe psoriasis and ulcerative colitis; AK111, an IL-17 monoclonal antibody to treat moderate-to-severe psoriasis and ankylosing spondylitis; and AK102, a PCSK9 monoclonal antibody to treat hypercholesterolemia. Further, its preclinical product includes AK127, a TIGIT monoclonal antibody to treat solid tumors; and AK115, a NGF monoclonal antibody. The company has collaboration agreements with Pfizer Pharmaceuticals, AstraZeneca Pharmaceuticals, and MD Anderson Medical Institute. Akeso, Inc. was founded in 2012 and is headquartered in Zhongshan, the People's Republic of China.